IOBT Financial Statements From 2010 to 2025

Stocks . USA . 
Stock . IO Biotech
IOBT Stock  USD 0.74  0.04  5.71%   
Analyzing historical trends in various income statement and balance sheet accounts from IO Biotech's financial statements helps investors evaluate the company's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting IO Biotech's valuation are summarized below:
Gross Profit
-2.6 M
Market Capitalization
53.2 M
Earnings Share
(1.34)
There are currently one hundred twenty fundamental measures for IO Biotech that can be evaluated and compared over time across peers in the sector. All traders should confirm IO Biotech's latest fundamentals against the performance from 2010 to 2025 and make sure the trends continue to evolve in the right direction. Market Cap is likely to gain to about 135.3 M in 2025, whereas Enterprise Value is likely to drop slightly above 2.7 M in 2025.
Check IO Biotech financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among IO Biotech's main balance sheet or income statement drivers, such as Net Interest Income of 5 M, Depreciation And Amortization of 806.5 K or Interest Expense of 3.3 K, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 1.35. IOBT financial statements analysis is a perfect complement when working with IO Biotech Valuation or Volatility modules.
  
Build AI portfolio with IOBT Stock
Check out the analysis of IO Biotech Correlation against competitors.
For more information on how to buy IOBT Stock please use our How to Invest in IO Biotech guide.

IO Biotech Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets111.4 M67.7 M50.2 M
Slightly volatile
Short and Long Term Debt Total3.2 M1.9 M6.4 M
Slightly volatile
Other Current Liabilities7.6 M14.1 M3.7 M
Slightly volatile
Total Current Liabilities12.8 M19.5 M11.3 M
Slightly volatile
Other Liabilities61 K67.8 K55.3 K
Slightly volatile
Current Deferred Revenue758.4 K853.2 K930.2 K
Slightly volatile
Accounts Payable3.3 M4.7 M1.9 M
Slightly volatile
Cash104.2 M60 M46.5 M
Slightly volatile
Non Current Assets Total1.9 M2.7 M779.3 K
Slightly volatile
Non Currrent Assets Other132.6 K117 K64.7 K
Slightly volatile
Other Assets1.091.1570 K
Pretty Stable
Cash And Short Term Investments104.2 M60 M46.5 M
Slightly volatile
Net Receivables1.1 M1.1 M1.3 M
Pretty Stable
Common Stock Shares Outstanding69.2 M65.9 M15.6 M
Slightly volatile
Liabilities And Stockholders Equity111.4 M67.7 M50.2 M
Slightly volatile
Non Current Liabilities Total1.1 M1.2 M2.8 M
Pretty Stable
Other Current Assets3.7 M3.8 M1.7 M
Slightly volatile
Other Stockholder Equity269.3 M413.1 M109.5 M
Slightly volatile
Total Liabilities13.8 M20.7 M11.7 M
Slightly volatile
Short and Long Term Debt6.9 M7.8 M8.5 M
Slightly volatile
Total Current Assets109.5 M65 M49.5 M
Slightly volatile
Capital Stock45.1 K75.9 K34.6 K
Slightly volatile
Non Current Liabilities Other2.7 M2.6 M659.5 K
Slightly volatile
Short Term Debt681.1 K717 K5.6 M
Slightly volatile
Common Stock41.4 K75.9 K33.1 K
Slightly volatile
Property Plant And Equipment Net2.4 M2.4 M812.4 K
Slightly volatile
Property Plant And Equipment Gross2.7 M2.9 M893.9 K
Slightly volatile
Property Plant Equipment492.8 K852.1 K292.9 K
Slightly volatile
Common Stock Total Equity23.2 K26.1 K28.5 K
Slightly volatile
Capital Surpluse261.4 M294 M320.6 M
Slightly volatile

IO Biotech Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization806.5 K849 K7 M
Slightly volatile
Interest Expense3.3 K3.5 K47.4 K
Slightly volatile
Selling General Administrative15.9 M23.7 M7.5 M
Slightly volatile
Other Operating Expenses58.5 M95.2 M29.2 M
Slightly volatile
Research Development42.7 M71.5 M21.7 M
Slightly volatile
Total Operating Expenses58.2 M94.3 M29 M
Slightly volatile
Income Tax Expense1.5 M1.4 M327.3 K
Slightly volatile
Reconciled Depreciation587.4 K849 K171.6 K
Slightly volatile
Cost Of Revenue786.5 K849 K588.2 K
Slightly volatile
Non Operating Income Net Other1.2 M1.4 M1.5 M
Slightly volatile
Selling And Marketing Expenses604.8 K680.4 K741.8 K
Slightly volatile

IO Biotech Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Net Borrowings7.2 M8.1 M8.8 M
Slightly volatile
Stock Based Compensation4.3 M6.5 M1.8 M
Slightly volatile
Begin Period Cash Flow94.8 M143.5 M42.7 M
Slightly volatile
Depreciation891.5 K849 K191.3 K
Slightly volatile
Capital Expenditures41.8 K44 K183.4 K
Pretty Stable
End Period Cash Flow104.4 M60.3 M46.5 M
Slightly volatile
Change To Netincome10.4 M7.9 M4.5 M
Slightly volatile
Cash Flows Other Operating4 M4.5 M4.9 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Capex To Depreciation0.04920.051857.4879
Slightly volatile
Payables Turnover0.140.18210.1419
Slightly volatile
Cash Per Share0.870.911228.8082
Slightly volatile
Days Payables Outstanding2.4 K2 K2.6 K
Slightly volatile
Income Quality0.640.86240.8046
Slightly volatile
Current Ratio3.173.33323.8621
Slightly volatile
Capex Per Share6.0E-47.0E-40.006
Very volatile
Interest Debt Per Share0.02760.029130.6256
Slightly volatile
Debt To Assets0.02690.02830.5825
Slightly volatile
Days Of Payables Outstanding2.4 K2 K2.6 K
Slightly volatile
Ebt Per Ebit1.250.98811.1139
Pretty Stable
Quick Ratio3.173.33323.842
Slightly volatile
Net Income Per E B T0.811.01530.9914
Slightly volatile
Cash Ratio2.933.08073.5849
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.111.00051.0107
Slightly volatile
Debt Ratio0.02690.02830.5825
Slightly volatile

IO Biotech Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap135.3 M69.7 M156.5 M
Slightly volatile

IOBT Fundamental Market Drivers

IOBT Upcoming Events

12th of March 2024
Upcoming Quarterly Report
View
9th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
12th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About IO Biotech Financial Statements

IO Biotech shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although IO Biotech investors may analyze each financial statement separately, they are all interrelated. The changes in IO Biotech's assets and liabilities, for example, are also reflected in the revenues and expenses on on IO Biotech's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue853.2 K758.4 K
Cost Of Revenue849 K786.5 K

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for IOBT Stock Analysis

When running IO Biotech's price analysis, check to measure IO Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy IO Biotech is operating at the current time. Most of IO Biotech's value examination focuses on studying past and present price action to predict the probability of IO Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move IO Biotech's price. Additionally, you may evaluate how the addition of IO Biotech to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2025 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY